Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial
Induction nivolumab before CRT did not meet the predefined feasibility threshold because of reduced cisplatin dosing after toxicity in 10% of patients. The relapse incidence was numerically lower in the EA but this finding is exploratory and requires confirmation.
Authors
- F. Clatot
- P. Blanchard
- A.-L. Gaultier (ORCID: https://orcid.org/0009-0003-9671-2343)
- Y. TAO
- Alicia Larive
- François Bidault (ORCID: https://orcid.org/0000-0002-5566-9372)
- H. Mirghani (ORCID: https://orcid.org/0000-0003-0043-0185)
- B. Morin
- Hélène Péré (ORCID: https://orcid.org/0000-0002-3225-4238)
- Lionnel Geoffrois
- Laure Monard (ORCID: https://orcid.org/0000-0001-6731-1450)
- J. Fayette
- Éric Tartour
- Michaël Chevrot
- Cécile Badoual
- Emmanuelle Fabiano (ORCID: https://orcid.org/0000-0002-0234-7580)
- Julien Puech
- France Nguyen
- Lea Picavet
- David Veyer
- Benoit Calderon
- Sarah Kreps
- Aicha Ben Hariz
- Caroline Even
- Anne Aupérin
Institutions
- Inserm (FR)
- Université d'Avignon et des Pays de Vaucluse (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre de Recherche des Cordeliers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut de Cancérologie de Lorraine (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Centre Léon Bérard (FR)
- Hôpital Européen (FR)
- Paris Cardiovascular Research Center (FR)
- Génomique Fonctionnelle des Tumeurs Solides (FR)
- UniCancer Group (FR)
- Centre Virchow-Villermé (FR)
- Institut Sainte Catherine (FR)
- Centre Henri Becquerel (FR)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1200/jco-25-00835
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00